677 related articles for article (PubMed ID: 35384056)
41. Repositioning of anti-dengue compounds against SARS-CoV-2 as viral polyprotein processing inhibitor.
Bajrai LH; Faizo AA; Alkhaldy AA; Dwivedi VD; Azhar EI
PLoS One; 2022; 17(11):e0277328. PubMed ID: 36383621
[TBL] [Abstract][Full Text] [Related]
42. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
43. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
[TBL] [Abstract][Full Text] [Related]
44. Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors.
Khorsandi Z; Afshinpour M; Molaei F; Askandar RH; Keshavarzipour F; Abbasi M; Sadeghi-Aliabadi H
J Biomol Struct Dyn; 2022 Oct; 40(17):7940-7948. PubMed ID: 33784944
[TBL] [Abstract][Full Text] [Related]
45. Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study.
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2022 Mar; 40(5):2053-2066. PubMed ID: 33094701
[TBL] [Abstract][Full Text] [Related]
46. Identification of novel inhibitors of SARS-CoV-2 main protease (M
Verma S; Patel CN; Chandra M
J Comput Chem; 2021 Oct; 42(26):1861-1872. PubMed ID: 34287986
[TBL] [Abstract][Full Text] [Related]
47. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
Mandour YM; Zlotos DP; Alaraby Salem M
J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
[TBL] [Abstract][Full Text] [Related]
48. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
Elzupir AO
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
[TBL] [Abstract][Full Text] [Related]
49. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.
Gentile D; Patamia V; Scala A; Sciortino MT; Piperno A; Rescifina A
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32340389
[TBL] [Abstract][Full Text] [Related]
50. Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main protease) of SARS-CoV-2.
Shode FO; Idowu ASK; Uhomoibhi OJ; Sabiu S
J Biomol Struct Dyn; 2022 Sep; 40(14):6587-6602. PubMed ID: 33590806
[TBL] [Abstract][Full Text] [Related]
51. Computational Determination of Potential Multiprotein Targeting Natural Compounds for Rational Drug Design Against SARS-COV-2.
Muhseen ZT; Hameed AR; Al-Hasani HMH; Ahmad S; Li G
Molecules; 2021 Jan; 26(3):. PubMed ID: 33525411
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2021 Aug; 39(12):4362-4374. PubMed ID: 32568613
[TBL] [Abstract][Full Text] [Related]
53. Chetomin, a SARS-CoV-2 3C-like Protease (3CL
Ibrahim MAA; Abdelrahman AHM; Mohamed DEM; Abdeljawaad KAA; Naeem MA; Gabr GA; Shawky AM; Soliman MES; Sidhom PA; Paré PW; Hegazy MF
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680290
[TBL] [Abstract][Full Text] [Related]
54. In silico study of alkaloids with quercetin nucleus for inhibition of SARS-CoV-2 protease and receptor cell protease.
Mohebbi A; Eskandarzadeh M; Zangi H; Fatehi M
PLoS One; 2024; 19(4):e0298201. PubMed ID: 38626042
[TBL] [Abstract][Full Text] [Related]
55. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
Kandeel M; Al-Nazawi M
Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
[TBL] [Abstract][Full Text] [Related]
56. Discovery of a "Cocktail" of Potential SARS-COV-2 Main Protease Inhibitors through Virtual Screening of Known Chemical Components of Vitex negundo L. ("Lagundi").
Cayona R; Creencia E
Med Chem; 2022; 18(3):364-381. PubMed ID: 34148541
[TBL] [Abstract][Full Text] [Related]
57. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
[TBL] [Abstract][Full Text] [Related]
58.
Kumar B; Parasuraman P; Murthy TPK; Murahari M; Chandramohan V
J Biomol Struct Dyn; 2022 Oct; 40(17):7796-7814. PubMed ID: 33759690
[TBL] [Abstract][Full Text] [Related]
59. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
[TBL] [Abstract][Full Text] [Related]
60. Searching possible SARS-CoV-2 main protease inhibitors in constituents from herbal medicines using
Rasul HO; Thomas NV; Ghafour DD; Aziz BK; Salgado M G; Mendoza-Huizar LH; Candia LG
J Biomol Struct Dyn; 2024 May; 42(8):4234-4248. PubMed ID: 37349945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
